This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Melder, R. J. Articles by Herberman, R. B. Search for Related Content PubMed PubMed Citation Articles by Melder, R. J. Articles by Herberman, R. B.

A New Approach to Generating Antitumor Effectors for Adoptive Immunotherapy Using Human Adherent Lymphokine-activated Killer Cells

Department of Pathology [R. J. M., T. L. W., J. C. H., R. B. H.], Division of Clinical Immunopathology [T. L. W.] and Department of Medicine [R. B. H.], University of Pittsburgh School of Medicine and Pittsburgh Cancer Institute [R. J. M., T. L. W., N. L. V., J. C. H., R. B. H.], Pittsburgh, Pennsylvania 15261

Lymphocytes from human peripheral blood incubated with interleukin-2 (IL2) develop lymphokine-activated killer (LAK) activity with the ability to kill a wide variety of tumor cells in a non-major histocompatibility complex-restricted manner. Adoptive immunotherapy with LAK cells and IL2 has been reported to lead to a regression of solid tumors in some patients with advanced malignancies. Aiming to improve the effectiveness of clinical adoptive immunotherapy, we developed a procedure for selective enrichment from human blood mononuclear cells (MNC) of IL2-activated antitumor effector cells. These cells, termed adherent LAK (A-LAK) cells because of their characteristic property of adherence to plastic, demonstrated both higher proliferative potential and greater antitumor cytotoxicity than unseparated MNC. Human A-LAK cells represented only 1 to 4% of IL2-activated MNC at 24 h but expanded from 130- to 1100-fold in 20 days. They comprised a population highly enriched in CD3-Leu19+ effector cells with antitumor activity against fresh human solid tumor cells and established cell lines. A-LAK cells retained antitumor activity for up to 14 days when cultured in the presence of IL2. They also mediated antibody-dependent cytotoxicity. Large-scale generation of A-LAK cells from the blood of patients with cancer proved feasible and should yield populations that are effective in vivo at lower doses than those required with unseparated LAK cells. This offers the potential for improving the antitumor effects, reducing the toxicity, and facilitating the administration of adoptive immunotherapy in humans. A Phase I/II clinical trial utilizing A-LAK cells and IL2 in patients with melanoma and renal cell carcinoma is now in progress.

¹ To whom requests for reprints should be addressed, at One Children's Place, Room 5725, 3705 Fifth Avenue, Pittsburgh, PA 15213-3417.

² On sabbatical leave from the Institute of Oncology and Radiology, Pasterova M, 11000 Belgrade, Yugoslavia.

Received 11/ 7/87. Revised 3/14/88. Accepted 3/18/88.

This article has been cited by other articles:

				S.-Y. Rah, K.-H. Park, T.-S. Nam, S.-J. Kim, H. Kim, M.-J. Im, and U.-H. Kim Association of CD38 with Nonmuscle Myosin Heavy Chain IIA and Lck Is Essential for the Internalization and Activation of CD38 J. Biol. Chem., February 23, 2007; 282(8): 5653 - 5660. [Abstract] [Full Text] [PDF]

				S.-Y. Rah, K.-H. Park, M.-K. Han, M.-J. Im, and U.-H. Kim Activation of CD38 by Interleukin-8 Signaling Regulates Intracellular Ca2+ Level and Motility of Lymphokine-activated Killer Cells J. Biol. Chem., January 28, 2005; 280(4): 2888 - 2895. [Abstract] [Full Text] [PDF]

				A. A. Maghazachi G protein-coupled receptors in natural killer cells J. Leukoc. Biol., July 1, 2003; 74(1): 16 - 24. [Abstract] [Full Text] [PDF]

				M. Inngjerdingen, B. Damaj, and A. A. Maghazachi Expression and regulation of chemokine receptors in human natural killer cells Blood, January 15, 2001; 97(2): 367 - 375. [Abstract] [Full Text] [PDF]